American Injectables announced that the company has successfully completed the commissioning and qualification of its newly constructed facility in addition to the completion of Series A financing.
Key accomplishments were qualifying the facility and utilities as well as completing the first successful series of media fills for the sterile core and vial filling line. During a recent interview, CEO Adam Levitt made these comments,
“We are excited to start registration batches for FDA submission in the coming months and preparing for our first FDA inspection and approval.”
Mr. Levitt went on to say, “I am further announcing the addition of Dr Vijay Nekkanti, VP R&D to the leadership team. Dr Nekkanti most recently was leading R&D for Humanwell and has held leadership roles with Custopharm, and Dr. Reddy’s Lab and Pfizer. I am very excited about this new critical hire. American Injectables, Inc is now well-positioned with Integrated Product Development and Manufacturing engine that quickly and flexibly brings new products to market. With the addition of Dr. Nekkanti we have completed building a world class leadership team.”
Chairman Subhanu Saxena said, “I am delighted to see American Injectables progress with this round of funding. This successful funding round reflects the success we’ve achieved through facility qualification and completion of media fills. The focus and dedication of the entire organization is to become an important US-based supplier of essential medicines to the acute care market, and to become a partner of choice for industry through their sterile manufacturing of vials and ready-to-use prefilled syringe products.”
[Bourne Partners advised American Injectables in the fundraising.]